MabThera use to double with first line indication

August 11, 2004

Roche's cancer drug MabThera (rituximab) has received European approval for a new indication – the first line treatment of indolent …

Developing people developing drugs

August 9, 2004

What distinguishes pharma research and development from other high-tech industries? It is an oddity of pharma research R&D that, despite …

FDA approves Lipitor for reducing heart attack risk

August 5, 2004

The FDA has approved Pfizer's cholesterol-lowering statin Lipitor for a new indication – the prevention of cardiovascular disease by reducing …

Pharma to work with NPC on pre-launch updates

August 4, 2004

News of new medicines on the horizon should be communicated better and earlier to NHS clinicians and managers following a …

‘Double boost’ for Seoquel in bipolar disorder and dementia

August 4, 2004

AstraZeneca announced a 'double boost' for its atypical antipsychotic Seroquel as it gained FDA approval for the long-term treatment of …

Lilly to disclose clinical trial results

August 4, 2004

Lilly has responded to calls for greater disclosure of clinical trial results by pledging to publish more data through its …

Turning clinical trials on their head

August 4, 2004

Increased pressure to get more products to market faster, with a close eye on the total cost of development and …

Trading places and switching sides

July 29, 2004

Power, intrigue, corruption and more than a dash of Hollywood: yes, the Mafia has it all. And just like La …

New diabetes drug superior to Lantus, says Lilly

July 29, 2004

Amylin Pharmaceuticals and partners Lilly say patients taking their new diabetes drug exenatide achieved similar glycaemic control to those on …

‘Patents versus patients’ still part of the problem

July 26, 2004

The head of the UN AIDS programme has said there must be an end to divisive "institutional agendas" and greater …

Vytorin poised to benefit from controversial US guidelines

July 26, 2004

New US guidelines for lowering cholesterol targets in at-risk patients have stirred controversy after experts were accused of not declaring …

R&D chief loses his cool over Swedish attitude

July 26, 2004

AstraZeneca says it remains committed to its research operations in Sweden – with its headquarters south-west of Stockholm – after …

The Gateway to Local Adoption Series

Latest content